Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the biosimilars portfolio expanded, while disciplined capital allocation and a Fitch upgrade strengthened the financial profile.Based on…
Q2 2026 saw revenues of $4.1B, with innovative brands up 43% YoY and generics down, leading to a net loss due to Emalex acquisition costs. 2026 guidance was raised for key brands, with improved gross margins and strong cash flow, despite ongoing risks and market pressures.Original document: Teva Ph…
Q2 2026 saw strong growth in innovative and biosimilar portfolios, offset by a decline in generics and a significant one-time impact from the Emalex acquisition. Guidance for 2026 was reaffirmed, with raised outlooks for key innovative products and continued focus on margin expansion and debt reduc…
Teva reported second-quarter 2026 revenue of $4.14 billion and a GAAP loss per share of $0.49, driven largely by a $726 million charge related to the Emalex acquisition and acquired IPR&D. Non-GAAP diluted EPS was $0.02 and adjusted EBITDA was $474 million; the company raised its 2026 outlook for i…
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and a favorable safety profile. The therapy's quarterly dosing and potential for broader autoimmune indications support its different…
A phase I-B study of an anti-IL-15 antibody in vitiligo showed 42% of patients achieved ≥50% facial improvement at 24 weeks with quarterly dosing, favorable safety, and strong patient-reported outcomes. The therapy is positioned for further development in vitiligo and related autoimmune diseases.Ba…
